Related Experiment Video

Updated: May 31, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Current systemic management of metastatic renal cell carcinoma - first line and second line therapy

Ian Wright1, Anil Kapoor

  • 1Genito Urinary Oncology Program, Juravinski Cancer Centre, G344-St. Joseph's Hospital, Hamilton, Ontario, Canada.

Current Opinion in Supportive and Palliative Care
|July 5, 2011
PubMed
Abstract

Insights

Targeted therapies have transformed metastatic renal cell carcinoma (mRCC) treatment, replacing older methods. While offering new hope, advanced renal cell carcinoma (RCC) still requires more effective, curative options.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) understanding has advanced, driving targeted therapy development.
  • Metastatic RCC (mRCC) treatment has evolved significantly in the past decade.

Purpose of the Study:

  • Review recent clinical trial data for approved first and second-line mRCC agents.
  • Discuss current therapeutic strategies and explore future treatment directions for mRCC.

Main Methods:

  • Analysis of clinical trial data for approved mRCC therapies.
  • Review of phase II and III studies for emerging treatments.

Main Results:

  • Approved agents include sunitinib, pazopanib, sorafenib, bevacizumab, temsirolimus, and everolimus.
  • These targeted therapies have demonstrated significant clinical benefits in phase III trials.
  • Targeted agents have largely replaced cytokines as first-line therapy for advanced and mRCC.

Conclusions:

  • The treatment landscape for mRCC has dramatically shifted, improving patient outlook.
  • Despite progress, mRCC remains incurable, necessitating further research for more effective treatments.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...